JP7821159B2 - Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 - Google Patents

Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子

Info

Publication number
JP7821159B2
JP7821159B2 JP2023509554A JP2023509554A JP7821159B2 JP 7821159 B2 JP7821159 B2 JP 7821159B2 JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023509554 A JP2023509554 A JP 2023509554A JP 7821159 B2 JP7821159 B2 JP 7821159B2
Authority
JP
Japan
Prior art keywords
single variable
variable domain
antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023509554A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022037527A5 (https=
JP2023537958A5 (https=
JP2023537958A (ja
Inventor
子 朋 甄
美 娟 謝
秀 貞 杜
毅 敏 馬
兵 張
同 杰 徐
喜 全 張
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2023537958A publication Critical patent/JP2023537958A/ja
Publication of JPWO2022037527A5 publication Critical patent/JPWO2022037527A5/ja
Publication of JP2023537958A5 publication Critical patent/JP2023537958A5/ja
Application granted granted Critical
Publication of JP7821159B2 publication Critical patent/JP7821159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023509554A 2020-08-20 2021-08-16 Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 Active JP7821159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842370 2020-08-20
CN202010842370.5 2020-08-20
PCT/CN2021/112756 WO2022037527A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (4)

Publication Number Publication Date
JP2023537958A JP2023537958A (ja) 2023-09-06
JPWO2022037527A5 JPWO2022037527A5 (https=) 2024-08-26
JP2023537958A5 JP2023537958A5 (https=) 2024-08-26
JP7821159B2 true JP7821159B2 (ja) 2026-02-26

Family

ID=80323410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509554A Active JP7821159B2 (ja) 2020-08-20 2021-08-16 Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子

Country Status (5)

Country Link
EP (1) EP4202047A4 (https=)
JP (1) JP7821159B2 (https=)
KR (1) KR20230045066A (https=)
CN (1) CN115715325A (https=)
WO (1) WO2022037527A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
BR112020006248A8 (pt) * 2017-09-29 2023-03-21 Mogam Inst Biomedical Res Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
UY38251A (es) * 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3845244A4 (en) * 2018-08-24 2022-09-07 Shenzhen Pregene Biopharma Co. Ltd. ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
CN111333729B (zh) * 2020-03-17 2022-12-06 深圳市南科生物工程有限公司 抗b细胞成熟抗原的纳米抗体及应用
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109942708A (zh) 2019-03-28 2019-06-28 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709A (zh) 2019-04-22 2019-06-28 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用

Also Published As

Publication number Publication date
KR20230045066A (ko) 2023-04-04
WO2022037527A1 (zh) 2022-02-24
EP4202047A1 (en) 2023-06-28
EP4202047A4 (en) 2024-09-18
US20230193292A1 (en) 2023-06-22
CN115715325A (zh) 2023-02-24
JP2023537958A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN115052895B (zh) 抗SIRPα抗体及其用途
JP7820383B2 (ja) グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
CA3089260A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN113412281A (zh) Btn3a结合蛋白及其用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
CN109721656B (zh) 靶向rankl的治疗性抗体
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
JP7821161B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2021197401A1 (zh) 结合cd47的抗原结合多肽及用途
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP7821159B2 (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
JP7773237B2 (ja) Ｃｄ４７に対する単一ドメイン抗体及びその用途
US12612635B2 (en) BCMA-binding single variable structural domain and antigen-binding molecule
JP7851924B2 (ja) 抗ｔｒｏｐ－２抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
JP7773238B2 (ja) Ｐｄ－ｌ１に対する単一ドメイン抗体及びその用途
TWI889920B (zh) 抗ｔｒｏｐ-２抗體、其抗原結合片段或其突變體、及其醫藥用途
CN110407942B (zh) 针对kn044的单域抗体
JP2026504831A (ja) ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及びそれらの医薬的使用
CN121532424A (zh) Btn3a结合蛋白及其医药用途
CN121895452A (zh) 抗激活素2型受体的抗体及其用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821159

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150